查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1628000

GLP-1受體激動劑市場機會、成長動力、產業趨勢分析及2024年至2032年預測

GLP-1 Receptor Agonist Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，全球GLP-1受體激動劑市場達到244億美元，預計2024年至2032年複合年成長率為9.7%。的。根據最近的研究，未來幾十年，糖尿病患者數量預計將增加一倍以上，這凸顯了對有效治療方案的迫切需求。

GLP-1 受體激動劑因其在控制第 2 型糖尿病和促進減肥方面的雙重功效而獲得了巨大的關注。這些藥物模仿天然腸促胰島素激素來調節血糖水平，同時幫助控制體重，並解決兩個關鍵的健康挑戰。隨著醫療保健提供者和患者尋求副作用最小的有效療法，對 GLP-1 受體激動劑的需求預計將急劇上升。藥物配方的進步和這些治療方法已被證實的益處正在進一步推動市場擴張。

依給藥途徑，市場分為腸胃外和口服兩類。以注射劑型為主的注射劑細分市場在2023 年佔據了最大的市場佔有率，預計到2032 年將保持領先地位。青睞，使其成為管理疾病的可靠選擇。儘管口服替代品不斷湧現，但注射劑因其良好的臨床成功和穩定的劑量能力而佔據主導地位。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 244億美元
預測值 557 億美元
複合年成長率 9.7%

市場按應用進一步分為第 2 型糖尿病、肥胖症和其他用途。 2 型糖尿病細分市場在 2023 年佔據最大佔有率，預計將經歷強勁成長。作為全球最普遍的慢性疾病之一，2 型糖尿病迫切需要有效的管理解決方案。 GLP-1 受體激動劑提供了一種創新方法，可提供血糖控制、體重管理的益處，滿足糖尿病護理的關鍵需求。

北美 GLP-1 受體激動劑市場預計到 2032 年將大幅成長。美國因其先進的醫療保健生態系統、大量的醫藥投資以及創新療法而脫穎而出。這些因素使北美成為全球 GLP-1 受體激動劑市場的關鍵驅動力。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 糖尿病和肥胖等慢性疾病的盛行率不斷上升
      • 增加研發活動以開發新療法
      • 口服GLP-1受體激動劑的製劑進展
      • 提高對糖尿病診斷和治療方案的認知
    • 產業陷阱與挑戰
      • 與少數 GLP-1 激動劑藥物相關的不良反應
      • 市場參與者召回產品
  • 成長潛力分析
  • 臨床試驗分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 全球公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀錶板

第 5 章：市場估計與預測：按藥物類別

  • 主要趨勢
  • 索馬魯肽
  • 度拉魯肽
  • 利拉魯肽
  • 艾塞那肽
  • 其他藥物類別

第 6 章：市場估計與預測：按給藥途徑

  • 主要趨勢
  • 注射用
  • 口服

第 7 章：市場估計與預測：按應用

  • 主要趨勢
  • 2型糖尿病
  • 肥胖
  • 其他應用

第 8 章：市場估計與預測：按配銷通路

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 9 章：市場估計與預測：按地區

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 瑞士
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Eli Lilly and Company
  • Sanofi
  • Novo-Nordisk A/S
  • AstraZeneca
  • Pfizer, Inc.
  • Amgen, Inc.
  • Innovent Biologics, Inc.
  • PegBio Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
簡介目錄
Product Code: 5864

The Global GLP-1 Receptor Agonist Market reached USD 24.4 billion in 2023 and is projected to grow at a CAGR of 9.7% from 2024 to 2032. This growth is primarily driven by the increasing prevalence of type 2 diabetes and obesity worldwide. According to recent research, the number of individuals living with diabetes is expected to more than double in the coming decades, highlighting the urgent need for effective treatment options.

GLP-1 receptor agonists have gained significant traction due to their dual efficacy in managing type 2 diabetes and promoting weight loss. These drugs mimic natural incretin hormones to regulate blood sugar levels while aiding in weight management, addressing two critical health challenges. As healthcare providers and patients seek effective therapies with minimal side effects, the demand for GLP-1 receptor agonists is expected to rise sharply. Advancements in drug formulations and the proven benefits of these treatments are further fueling market expansion.

By route of administration, the market is segmented into parenteral and oral categories. The parenteral segment, dominated by injectable formulations, accounted for the largest market share in 2023 and is anticipated to maintain its lead through 2032. Injectable GLP-1 receptor agonists are favored for their superior bioavailability and consistent efficacy, making them a reliable choice for managing diabetes and obesity. Although oral alternatives are emerging, injectables dominate due to their well-established clinical success and stable dosing capabilities.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$24.4 Billion
Forecast Value$55.7 Billion
CAGR9.7%

The market is further divided by application into type 2 diabetes, obesity, and other uses. The type 2 diabetes segment held the largest share in 2023 and is expected to experience robust growth. As one of the most widespread chronic diseases globally, type 2 diabetes drives a significant need for efficient management solutions. GLP-1 receptor agonists provide an innovative approach by offering glycemic control weight management benefits, addressing a critical need in diabetes care.

North America GLP-1 receptor agonist market is set to grow substantially through 2032. High diabetes and obesity rates, combined with a strong healthcare infrastructure, contribute to the region's dominance. The United States stands out due to its advanced healthcare ecosystem, significant pharmaceutical investments, and access to innovative treatments. These factors position North America as a key driver of the global GLP-1 receptor agonist market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic diseases such as diabetes and obesity
      • 3.2.1.2 Increasing R&D activities for developing novel therapeutics
      • 3.2.1.3 Formulation advancements of oral GLP-1 receptor agonists
      • 3.2.1.4 Increasing awareness about diagnosis and treatment options for diabetes
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects associated with few GLP-1 agonist drugs
      • 3.2.2.2 Product recalls by market players
  • 3.3 Growth potential analysis
    • 3.3.1 By drug class
    • 3.3.2 By route of administration
    • 3.3.3 By application
    • 3.3.4 By distribution channel
  • 3.4 Clinical trial analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Global company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class (USD Million)

  • 5.1 Key trends
  • 5.2 Semaglutide
  • 5.3 Dulaglutide
  • 5.4 Liraglutide
  • 5.5 Exenatide
  • 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration (USD Million)

  • 6.1 Key trends
  • 6.2 Parenteral
  • 6.3 Oral

Chapter 7 Market Estimates and Forecast, By Application (USD Million)

  • 7.1 Key trends
  • 7.2 Type 2 diabetes mellitus
  • 7.3 Obesity
  • 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel (USD Million)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region (USD Million)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Switzerland
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East & Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

  • 10.1 Eli Lilly and Company
  • 10.2 Sanofi
  • 10.3 Novo-Nordisk A/S
  • 10.4 AstraZeneca
  • 10.5 Pfizer, Inc.
  • 10.6 Amgen, Inc.
  • 10.7 Innovent Biologics, Inc.
  • 10.8 PegBio Co., Ltd.
  • 10.9 Sun Pharmaceutical Industries Ltd.
  • 10.10 Boehringer Ingelheim International GmbH